Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure  by Lewis, Eldrin F. et al.
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OBJECTIVES We sought to characterize decisions regarding listing of heart transplant candidates and to
determine the impact of delayed listing for a transplant on survival.
BACKGROUND Evaluation and listing for heart transplantation have evolved over the past decade, with the
complex decision process often extending beyond the time of initial review. Little is known
about the current impact of decisions and timing of listing on outcomes.
METHODS Decisions were prospectively recorded during the initial committee discussions regarding
patients referred for heart transplant evaluation. Survival and transplantation rates were
assessed.
RESULTS A total of 214 patients were evaluated for heart transplantation (age 49  11 years, ejection
fraction 21  9%, New York Heart Association class III  I, peak oxygen consumption 13
 4 ml/kg/min). At the initial evaluation, 44% of patients were deemed eligible, 25% were
potentially eligible, 19% were ineligible, and 12% were deferred. For eligible patients, 37% of
patients were listed within 10 days of evaluation, and a total of 71% of patients were ever
listed. Regardless of transplantation, the three-year survival rate in eligible patients not listed
early was similar to that in patients listed immediately (85% vs. 77%, p 0.34). Ineligible and
potentially eligible patients had a higher three-year mortality rate than did eligible patients if
transplantation occurred (51% vs. 17%, p  0.001) or not (57% vs. 19%, p  0.04).
CONCLUSIONS Using current accepted guidelines, many patients referred for transplant evaluation were not
considered eligible for transplantation, and those who were eligible were not often listed
immediately. Eligible patients not listed initially did well in the long term, and patients with
relative contraindications had worse outcomes with or without a transplant. (J Am Coll
Cardiol 2004;43:794–802) © 2004 by the American College of Cardiology Foundationt
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whe overall prevalence of heart failure (HF) continues to
ncrease in the U.S., with an estimated five million people
ffected (1). This changing prevalence is partly related to
mproved survival of patients with an acute myocardial
nfarction, an increasingly older population, and expanded
edical and surgical options for the management of ad-
See page 803
anced HF. Although the prevalence of HF increases, the
umber of suitable donor hearts has remained relatively
onstant, with 2,000 to 2,500 heart transplantations
erformed annually in the U.S. (2,3). The increasing num-
er of patients with advanced HF who may benefit from
eart transplantation, coupled with the limited donor pool,
as resulted in long waiting times before transplantation, as
ell as potentially increased mortality for those awaiting a
ransplant.
From the *Cardiovascular Division and †Cardiovascular Surgery, Brigham and
omen’s Hospital, Harvard Medical School, Boston, Massachusetts. Dr. Lewis was
upported in part by Grant 1 F32 HL71449-01 from the National Heart, Lung, and
lood Institute, National Institutes of Health, Bethesda, Maryland.
Manuscript received June 16, 2003; revised manuscript received October 15, 2003,tccepted October 20, 2003.The evaluation process and listing practices for heart
ransplantation have evolved over the past 10 years (4).
ncreasing therapeutic options for these patients have con-
ributed to longer periods of stability before transplantation.
oreover, patients with relative contraindications are more
ikely to be listed and transplanted than in the past because
f improved management strategies. However, little is
nown about the impact of delaying listing in suitable
andidates for heart transplantation undergoing current
ontemporary management. The objectives of this study
ere to characterize how a contemporary transplant com-
ittee makes decisions regarding the listing of transplant
andidates and to determine the impact of early listing
ersus delayed listing for a transplant on survival among
ligible transplant candidates.
ETHODS
tudy design and patient population. This is a prospec-
ive cohort study of patients with a history of HF, referred
o Brigham and Women’s Hospital for evaluation for heart
ransplantation between January 1997 and January 2000.
he multidisciplinary Transplant Committee met on a
eekly basis, and decisions regarding the suitability andiming of listing for each patient were made by the com-
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March 3, 2004:794–802 Outcomes of Potential Transplant Candidatesittee. Demographic data, cause of HF, duration of HF,
ew York Heart Association (NYHA) functional status,
chocardiographic and cardiac catheterization data, exercise
est results, and committee decisions regarding transplanta-
ion were recorded for all patients. Listed patients who were
table enough for outpatient management were seen by a
F/transplant cardiologist at least once a month. Routinely,
ll attempts were made to optimize medical therapy and
tabilize the patients’ hemodynamic status at the time of the
nitial evaluation. The majority of nonlisted patients re-
eived close follow-up at our institution, with referring
hysicians. Although none of the nonlisted patients received
transplant at another transplant center in the New
ngland region, transplantation outside of that region
ight not have been recognized. The study protocol was
eviewed and approved by the Institutional Review Board.
efinition of initial decisions. At the initial evaluation by
he Transplant Committee, patients were grouped into four
istinct decision categories. 1) Patients without heart trans-
lant contraindications were deemed “eligible” candidates
nd were thought to be good candidates for transplantation
ithout further evaluation. 2) Patients who were possible
andidates but had relative transplant contraindications that
osed some concern for an adverse outcome were deemed
potentially eligible” candidates. These patients often re-
uired further testing and observation to ascertain their
uitability for a transplant. 3) Patients with obvious contra-
ndications to transplantation were deemed “ineligible” can-
idates. 4) Finally, patients who did not complete the
ransplant evaluation or appeared too healthy after imme-
iate consideration for a transplant were “deferred” candi-
ates, who, in some cases, had evaluations interrupted due
o other cardiac surgery or patient reluctance to consider
ransplantation.
All patients eventually listed for a transplant were fol-
owed to determine the impact of the mean waiting time on
he transplant list, transplant rate, and effect of time of
isting relative to the evaluation date on overall survival.
atients who were listed within 10 days of completion of
heir transplant evaluation were considered “early-listed”
atients. Patients listed over 10 days after their initial
valuation were considered “delayed-listed” patients.
ata acquisition and statistical analysis. All patients were
ollowed prospectively to determine whether they were
isted for a transplant; the time of listing and time of
Abbreviations and Acronyms
AICD  automatic implantable cardioverter-defibrillator
HF  heart failure
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
UNOS  United Network for Organ Sharing
VAD  ventricular assist device
VO2  oxygen consumptionransplant were recorded, if applicable. Among transplanted catients, the United Network for Organ Sharing (UNOS)
tatus at the time of listing and the time of transplant was
ecorded. Status 1 incorporates the more recent 1A and 1B
ubcategories and is reserved for patients hospitalized and
equiring either mechanical circulatory support or positive
notropic support, whereas status 2 is reserved for all other
ctive patients who are not as critically ill (5). All-cause
ortality was assessed for each patient and confirmed using
he Social Security Death Index.
Differences between patients in the four decision groups,
s well as patients listed early and those not listed early, were
ssessed using the chi-square test for categorical variables
nd one-way analysis of variance for continuous variables.
aplan-Meier curves were created to demonstrate overall
urvival as well as survival of the subgroups from the time of
nitial evaluation. Differences in survival were compared by
he log-rank test. Evaluation of the effect of “early listing”
ersus “delayed listing” was performed using the Cox
roportional hazards model. Two models were created: one
odel included follow-up with and without heart transplan-
ation for all patients, and the second model censored
atients at the time of heart transplantation, thus measuring
edical survival only.
ESULTS
atient characteristics and committee decisions. A total
f 214 patients were evaluated for heart transplantation
uring the study period, with a mean follow-up of 26
onths. The patient population undergoing transplant
valuation had a mean age of 49  11 years, a left
entricular ejection fraction (LVEF) of 21  9%, peak
xygen consumption (VO2) of 13  4 ml/kg/min, and a
uration of HF of approximately four years. After excluding
ix patients who died in the hospital without being listed, a
otal of 158 patients (76%) received at least one follow-up
isit at the cardiomyopathy center at our institution, and 50
24%) received follow-up elsewhere.
A total of 95 patients (44%) were deemed eligible
andidates and 53 patients (25%) were potentially eligible
andidates for heart transplantation at the time of initial
valuation; 19% of the patients were thought to be poor
andidates for transplantation, and the decision was de-
erred in 12% of patients. Potentially eligible patients often
ad a history of cancer with uncertain remission status,
o-morbid illnesses, potentially reversible pulmonary vascu-
ar resistance, impaired renal function, obesity requiring
eight loss, or borderline compliance before listing. The
ajor reasons for ineligibility were similar co-morbid ill-
esses (e.g., diabetes with end-organ damage and renal
ailure), noncompliant behavior (e.g., ongoing smoking and
oor adherence to medication regimens), fixed pulmonary
ypertension, and persistent severe obesity with percent
deal body weight 140%. Patients were often deferred for
isting due to potential or ongoing improvement in their
linical status. Potentially eligible and ineligible patients
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Outcomes of Potential Transplant Candidates March 3, 2004:794–802ere more likely to have diabetes and chronic renal insuf-
ciency than eligible patients (Table 1). Eligible patients
ad a longer duration of diagnosed HF than potentially
ligible, ineligible, or deferred patients (p 0.001) and were
ore likely to have an automatic implantable cardioverter-
efibrillator (AICD), either at the time of evaluation or
hortly thereafter (p  0.02). Eligible and potentially
ligible patients tended to have more advanced HF. There
as no significant difference between the groups with regard
o age, gender, race, LVEF, peak VO2, or percentage of
atients achieving a peak respiratory exchange ratio of1.2.
t baseline, there were no differences in the use of
ngiotensin-converting enzyme inhibitors, diuretics,
igoxin, beta-blockers, inotropes, or aspirin.
Eighty patients (37%) were eventually listed for heart
ransplantation, with a mean time between evaluation and
isting of 85  203 days. As expected, eligible patients were
ost likely to be listed for a transplant at some point (71%),
ith only 8 (15%) of the potentially eligible candidates ever
etting listed for transplantation (Fig. 1). One patient who
as initially ineligible for a transplant was eventually listed,
able 1. Baseline Characteristics Based on Initial Committee De
Variable
Eligible
(n  95)
Pot
ge (yrs) 49  11
ale (%) 70
hite (%) 86
oronary artery disease (%) 38
eft ventricular ejection fraction (%) 22  9
VEDD (mm) 68  14
ew York Heart Association class (%)
I 7
II 14
III 56
IV 23
rthopnea (%) 47
eak VO2 (ml/kg/min) 13.0  4
eak RER 1–1.2 (%) 56
eak RER 1.2 (%) 37
odium (mEq/l) 136.0  6.0
reatinine (mg/dl) 1.2  0.7
uration of HF (yrs) 4.7  5.8
o-morbid illnesses (%)
Diabetes 27
Chronic renal insufficiency 21
Lung disease 24
edications (%)
ACE/ARB 81
Beta-blockers 33
Diuretics 85
Aspirin 22
Digoxin 78
Inotropes 7
Amiodarone 16
ICD 41
ata are presented as the mean value  SD or percentage of patients.
ACE  angiotensin-converting enzyme; AICD  automatic implantable cardiove
entricular end-diastolic diameter; RER  respiratory exchange ratio; VO2  oxygend four deferred patients were eventually listed. viming of listing. Among 67 (71%) of 95 eligible patients
ventually listed for a transplant, 35 (52%) were listed
ithin 10 days of evaluation (mean time from evaluation to
isting 2 3 days) and are classified as “early-listed patients”
Fig. 1). Among the 60 eligible patients not listed early after
he evaluation, only 32 (53% of remaining patients) were
ventually listed for a transplant (mean time from evaluation
o listing 111  144 days). When comparing the baseline
haracteristics between patients listed within 10 days and
atients not listed early (Table 2), the patients listed early
ad less left ventricular dilation (left ventricular end-
iastolic diameter 63 vs. 72 mm, p  0.01) and lower peak
O2 (11.4 vs. 13.3 ml/kg/min, p  0.02). Early-listed
atients were initially listed as a UNOS status 1 more
requently than delayed-listed patients (45% vs. 20%, p 
.04). Patients who were never listed tended to have less
oronary artery disease than the listed patients (29% vs.
2%, p  0.23). There were no significant differences
etween the listed and nonlisted patients with respect to
ge, race, gender, or LVEF. There was also no difference in
he use of AICD between listed and nonlisted patients (39%
lly Eligible
53)
Ineligible
(n  40)
Deferred
(n  26) p Value
 11 50  10 53  12 0.22
81 73 77 0.46
84 94 100 0.11
45 58 46 0.22
 8 21  8 21  9 0.89
 10 69  12 65  17 0.89
6 3 5 0.14
26 27 11
49 32 42
19 38 42
70 60 61 0.06
 6 11.6  4 13.0  3 0.33
53 64 25 0.61
33 18 75 0.24
 4.0 136.5  4.0 136.2  6.0 0.99
 0.5 1.5  0.7 1.3  0.6 0.40
 2.9 3.1  4.9 3.8  4.8 0.001
42 55 27 0.01
38 45 38 0.02
25 38 31 0.41
81 78 81 0.97
17 28 19 0.17
91 95 88 0.41
23 33 31 0.53
70 83 69 0.42
9 18 4 0.21
17 13 19 0.89
21 33 15 0.02
efibrillator; ARB  adrenergic receptor blocker; HF  heart failure; LVEDD  left
umption.cision
entia
(n 
47
21
68
13.8
136.4
1.2
3.2
rter-d
n conss. 46%, p  0.49). Seven of the patients (11%) who were
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March 3, 2004:794–802 Outcomes of Potential Transplant Candidatesventually listed underwent high-risk revascularization or
alve surgery, as compared with three of patients (11%) who
ere never listed (p  0.97). There were no deaths within
0 days of surgery.
Overall survival in the eligible group was excellent, with
7% one-year and 82% three-year survival rates, including
urvival with or without transplantation. Among 28 eligible
atients who were never listed for a transplant, only one
atient died during the mean 28-month follow-up period.
here was a trend toward improved survival in the eligible,
onlisted patients, as compared with all listed patients,
hen survival was assessed regardless of transplant status
Fig. 2A). The time of listing had no impact on late survival
igure 1. Distribution of patients based on decisions made by the Transpla
opulation listed in parentheses. The number (%) of patients who were lis
f evaluation were considered “early listed,” and patients listed after 10 da
Table 2. Baseline Characteristics of Eligible Pa
Variable
Early L
(n 
Age (yrs) 50 
Male (%) 66
White (%) 81
Coronary artery disease (%) 46
Left ventricular ejection fraction (%) 24 
LVEDD (mm) 63 
New York Heart Association class (%)
I 6
II 9
III 54
IV 31
Orthopnea (%) 50
Peak VO2 (ml/kg/min) 11.4 
Peak RER 1–1.2 (%) 79
Peak RER 1.2 (%) 21
Sodium (mEq/l) 135.4 
Creatinine (mg/dl) 1.3 
Duration of HF (yrs) 4.6 
AICD 40
UNOS status 1 at listing (%) 45
UNOS status 1 at transplant (%) 57
Data are presented as the mean value  SD or percentage o
Abbreviations as in Table 1.mong eligible patients, with similar outcomes between
atients not listed early and those listed early (Fig. 2A). The
ne-year survival rate in patients not listed early was 92%,
ompared with a rate of 80% in the early-listed patients (p
0.10). There was also no difference in the three-year
urvival rate (85% vs. 77%, p  0.34). Moreover, only six
atients died while actively listed for heart transplantation.
n the 35 patients listed early, three of the patients (8.6%)
ied awaiting a transplant, with a mean time to death after
isting of 65 days (range 30 to 111); one of three patients
nderwent implantation of a ventricular assist device (VAD)
efore death. The mean time to death after listing among
he three patients listed after 10 days after evaluation was
ommittee at the time of initial evaluation, with the percentage of the total
d transplanted in each group are described. Patients listed within 10 days
lowing the evaluation were considered “delayed-listed.”
s Based on Time of Listing
Late Listed
(n  32)
Never
Listed
(n  28) p Value
48  10 48  12 0.57
75 68 0.70
93 82 0.36
38 29 0.38
20  6 20  7 0.18
72  13 69  10 0.01
6 7 0.26
22 14
63 50
9 29
38 54 0.42
13.3  4 14.5  5 0.02
56 27 0.04
38 55 0.23
135.9  7.0 137.6  5.0 0.58
1.2  0.7 1.1  0.4 0.55
5.4  8.0 3.9  2.9 0.72
38 46 0.77
20 — 0.04
35 — 0.11
nts.nt C
ted antient
isted
35)
12
13
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4
5.0
0.8
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Outcomes of Potential Transplant Candidates March 3, 2004:794–80218 days (range 5 to 336), with one patient dying after VAD
mplantation. The risk of death was not different in the
elayed-listed patients compared with the early-listed pa-
ients, even after adjusting for NYHA, peak VO2, and left
entricular size (hazard ratio 0.71, 95% confidence interval
.29 to 1.79; p  0.47). There was also no difference in
ortality when censoring patients at the time of transplan-
ation, focusing only on pretransplant events (Fig. 2B).
A total of 54 (57%) of 95 initially eligible patients
igure 2. (A) Kaplan-Meier survival curves for all-cause mortality before
isting after the initial evaluation. Patients who are never listed have a trend
atients not listed early have survival similar to patients listed early for a
atients at the time of transplantation, to depict pretransplant mortality in e
ere no differences in survival between the patients not listed and the patventually underwent heart transplantation, representing p3% of all transplanted patients. Of these transplanted
atients, 12 (19%) underwent VAD support as a bridge to
ransplantation, and four (6%) underwent high-risk revas-
ularization or valve surgery between the time of evaluation
nd eventual heart transplantation. When comparing early-
isted and delayed-listed patients, there was no difference in
he waiting time to transplantation after the initial listing
127  126 vs. 141  174 days, p  0.75) or in the overall
ransplant rate (83% vs. 78%, p  0.63). The overall
fter transplantation in eligible patients (n  95) stratified by the time of
d better survival, compared with patients listed for a transplant (p 0.06).
lant. (B) Kaplan-Meier survival curves for all-cause mortality, censoring
e patients stratified by the time of listing after the initial evaluation. There
either listed early or late.and a
towar
transp
ligibl
ientsost-transplant mortality rate was similar in the two groups.
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March 3, 2004:794–802 Outcomes of Potential Transplant Candidateshree of the early-listed patients (10.3%) died within one
onth after transplantation, compared with none of the
elay-listed patients (p  0.10). By one year, there was no
ifference in the post-transplant mortality rate between
arly- and delayed-listed patients (17.2% vs. 16.0%, p 
.90), with the most common causes of death being early
raft failure and infection. This one-year mortality rate is
omparable to the national one-year post-transplant mor-
ality rate of 17.6% in 1999 (3). Five of the 67 eligible
atients who were initially listed were eventually deacti-
ated, and two patients remain active on the waiting list.
utcomes of patients not initially eligible. The chance of
isting and transplantation among those patients not initially
onsidered as eligible candidates was much lower, with only
(15%) of 53 potentially eligible patients, 4 (15%) of 26
eferred patients, and 1 (3%) of 40 ineligible patients ever
etting listed; 11 of 13 of these listed patients underwent
ransplantation (Table 3). The mean waiting time after
ransplant listing for these 11 candidates was 165 days, and
he other two listed patients have not died awaiting a
ransplant. However, 43% of the potentially eligible patients
nd 33% of the deferred patients required VAD support as
able 3. Outcomes Based on Initial Committee Decision
Variable
Eligible
(n  95)
t least 1 follow-up visit (%) 96
isted for transplant (%) 71
ean time to listing (days) 54  113
ransplanted (%) 57
ridge to transplant* (%) 15
ean time from listing to transplant (days) 135  152
eath before transplant (%) 7
eath after transplant (%) 20
igh-risk cardiovascular surgery (%) 11
0-Day survival† 100
entricular assist device (%) 13
Percentage of patients transplanted requiring support with a ventricular assist device
f patients or mean value  SD.
igure 3. Overall survival of patients with and without a transplant based
n the initial decision of the Transplant Committee. Potentially eligible
atients (hatched bars) had worse outcomes than eligible patients (solid
ars) both with and without a transplant. tbridge to transplantation, as compared with 15% of
ligible patients (p  0.16). Moreover, patients not initially
ligible had a tendency toward a higher three-year post-
ransplant mortality rate (Fig. 3) than transplanted patients
ho were initially thought to be eligible (57.1% vs. 20.4%,
 0.06). Finally, between 10% and 15% of patients
nderwent high-risk cardiovascular surgery with good 30-
ay survival, with the exception of two of four deferred
atients who died perioperatively (p  0.06).
Focusing only on the patients who did not receive a heart
ransplant, there still remains a significant difference in
urvival between the patients, based on the Transplant
ommittee’s initial decision (Fig. 4). Eligible patients had a
uch better survival than potentially eligible or ineligible
atients, with an 83% three-year survival rate. This survival
mong eligible patients is significantly better than the
hree-year survival of potentially eligible candidates (69%, p
0.02) and ineligible candidates (38%, p  0.001).
lthough patients ineligible for a transplant had a much
oorer outcome than the other groups, half of the deaths in
ntially Eligible
(n  53)
Ineligible
(n  40)
Deferred
(n  26) p Value
63 43 76 0.001
15 3 15 0.001
178  288 1,381 92  46 0.001
13 3 12 0.001
43 0 33 0.16
218  239 52 43  31 0.21
38 63 23 0.001
57 0 0 0.06
15 10 15 0.78
87 100 50 0.06
9 0 12 0.14
entage of survival among postsurgical patients. Data are presented as the percentage
igure 4. Kaplan-Meier survival curves for all-cause mortality before and
fter transplantation in all patients (n  214) stratified by the initial
ecision of the Transplant Committee. Eligible and deferred patients had
etter survival than patients who were potentially eligible or ineligible atPote
. †Perche time of the initial evaluation.
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Outcomes of Potential Transplant Candidates March 3, 2004:794–802his group of patients occurred within the first six months
fter the evaluation.
ISCUSSION
his study demonstrated that in applying currently accepted
riteria for heart transplant candidacy, the majority of
atients referred for a transplant are never listed, and those
ho are listed are not often listed immediately after the
nitial evaluation. Among the eligible candidates who were
ot believed to need immediate listing, there did not appear
o be a significant survival disadvantage to extending the
eriod of observation after the initial evaluation. Moreover,
he overall survival of eligible patients with advanced HF is
ood on medical therapy and is much better than the
urvival of patients who are not eligible for a transplant.
atients considered potentially eligible but not initially
ligible, because of various concerns, had more co-morbid
llnesses and seemed to do worse both with and without a
ransplant, despite being on a similar medical regimen.
Decision-making for patients with advanced HF is rap-
dly changing. Therefore, advanced HF programs must
valuate the increasingly complex medical therapies avail-
ble to determine the most optimal management plan for
ndividual patients. Because of these therapies, survival of
F patients is improving. As the one-year survival of many
F patients approaches that of newly transplanted patients,
he importance of careful and appropriate selection of
atients for heart transplantation increases.
This study characterized the decision process of a multi-
isciplinary Transplant Committee, as well as the impact of
hese decisions on survival. Less than half of patients
eferred to this transplant center were initially deemed to be
ligible for a transplant. Overall, approximately one-third of
atients referred for possible heart transplantation were ever
isted for a transplant, a rate that is similar to the rate of
isting described previously (6).
Among the eligible patients, those who were listed early
fter evaluation had more severe decompensation than did
hose patients not listed immediately, as demonstrated by
ower peak VO2 and a higher rate of initial listing as UNOS
tatus 1. Survival of the eligible patients who were medically
anaged was excellent and higher than the survival of
ost-transplant patients in this study, as well as the mean
ost-transplant survival reported by the Cardiac Transplant
esearch Database institutions (7). The early listing of
ligible patients who were thought by the Transplant
ommittee to have more severe decompensation may have
ontributed to the excellent survival among the remaining
atients on medical management.
There was no apparent detriment to delaying the time of
isting among other eligible patients. Over half of the
igh-risk cardiovascular surgeries were performed in pa-
ients who were not listed immediately after evaluation,
ith an excellent perioperative mortality rate. The number
f deaths among patients actively waiting for a transplant ias similar in both groups, and only one eligible patient
ied without being listed for a transplant. Moreover, early
eaths among the early-listed patients suggest that correct
isk stratification may have improved overall survival among
he listed group. Furthermore, delayed listing did not lead to
difference in post-transplant survival.
There are many potential benefits of not listing patients
mmediately after evaluation. At the time of evaluation,
ome patients may not have accepted their diagnosis and
rognosis. Patients’ estimation of their prognosis may im-
act their decisions (8). With a relatively fixed donor pool
nd more patients surviving to advanced HF, restriction of
he criteria for listing patients minimizes the waiting list for
transplant in the sickest population (9). There is evidence
hat restrictive criteria for heart transplantation may allow
ncreased survival for both transplanted and medically man-
ged patients (10). Deferring transplantation until necessary
ncreases the opportunity for advances in post-transplant
anagement to benefit the individual patient and may
otentially increase their overall survival, as the post-
ransplant course is still associated with a limited life-
xpectancy (11). Furthermore, patients on the waiting list
or a transplant may suffer more depressive symptoms and a
ecline in emotional well-being (12). Patients who improve
fter being listed may have a difficult time with the prospect
f being removed from the list and their loss of status as a
candidate.” The risks of postponing listing in earlier eras
ave diminished with the expanding use of AICD in
utpatients and with the option of VAD as a bridge to
ransplantation if the patient deteriorates (13).
Although the majority of eligible patients who were
edically managed were in NYHA class III or IV, the
verall survival in this group was better than that of
istorical controls. This potential improvement in survival
f these patients is supported by recent trials. The placebo
rms in recent trials describe a one-year mortality rate in
lass III and IV HF patients of 15% to 20% (14), which is
etter than the prognosis in the COoperative North Scan-
inavian ENalapril SUrvival Study (CONSENSUS) over a
ecade ago (15). Moreover, the excellent survival in carefully
elected patients who are eligible candidates for a transplant
uggests that the difference in survival between transplan-
ation and medical management among ambulatory patients
ay not be as great with current therapeutic options. With
he new therapeutic options available (14,16,17), there is an
ncreasing rationale for re-evaluating the optimal time of
isting (18). Thus, in patients in whom the Transplant
ommittee is not certain of the need to proceed immedi-
tely to transplantation, careful follow-up and re-evaluation
eem appropriate and adequate.
In comparison, patients who were ineligible candidates
ad a worse survival than eligible patients. These ineligible
atients did not undergo follow-up as often, partly due to
arly mortality after the evaluation and patient preference to
e seen locally. The survival of potentially eligible patients
nitially was not dramatically different from that of eligible
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March 3, 2004:794–802 Outcomes of Potential Transplant Candidatesatients; however, there was a gradual worsening of overall
urvival, with50% of patients dying by three years. In fact,
he relatively few patients who were eventually suitable
ransplant candidates were listed for a transplant usually
ithin one year of the initial evaluation and many required
AD support. Thus, the remainder of the patient popula-
ion, with more factors predicting advanced disease and
oorer prognosis, may have contributed to the eventual poor
verall survival in this potentially eligible group after the
rst year after evaluation. The patients who were ineligible
ad a significantly worse early and late mortality rate, with
ver 30% of the patients dying within six months of
valuation and three-quarters of the patients dying by three
ears. There are several potential reasons for this difference
n survival, including the degree of organ dysfunction
elated to HF chronicity, noncardiac co-morbidities, and
ehavior patterns jeopardizing compliance with a complex
edical regimen. The potentially eligible patients for whom
ome concerns existed had worse outcomes, as compared
ith eligible patients, regardless of eventual acceptance for a
ransplant. Moreover, for these potentially eligible patients
ho were eventually listed, the post-transplant mortality
ate was high, with almost half of the patients dying within
hree years after transplantation, as compared with a rate of
20% for initially eligible patients. Therefore, concern
egarding eligibility for listing in this group may be war-
anted by the trend for excess post-transplant mortality, and
he threshold for considering transplantation in the presence
f relative contraindications should remain high.
tudy limitations. There are several limitations of this
tudy. The small number of patients in each group limits
he analyses that can be reliably performed. The eligibil-
ty of patients for transplantation, as well as the time of
ndividual listing, was based on accepted criteria (2,19)
ut required subjective input from the Transplant Com-
ittee. This is a single-center study, and regional varia-
ions in the waiting time for a transplant may affect
isting patterns and outcomes. Less centralized follow-up
ay have influenced the outcomes of ineligible patients.
ome patients may have benefited from the expanding
ndications for AICD for primary prevention of sudden
ardiac death. However, the favorable outcomes both
efore and after transplantation suggest that many eligi-
le patients may be managed effectively by close surveil-
ance in a specialized transplant center.
onclusions. The decisions of the Transplant Committee
egarding patients referred for a heart transplant are not
requently finalized at the time of initial evaluation, and the
ajority of candidates are never listed. For eligible patients
ot believed to need immediate listing, there does not
ppear to be an adverse effect of delaying the time of listing.
ew of the potentially eligible patients were ever listed, and
his group of borderline transplant candidates had poorer
re- and post-transplant outcomes, compared with eligible
atients. The unfavorable overall outcomes in these border-ine patients both with and without a transplant justify 1ontinued careful evaluation of relative contraindications
nd future investigation to determine optimal management
trategies both with and without transplantation, including
he impact of these decisions on patients’ health-related
uality of life.
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